Value-based pricing (VBP) ideally takes advantage of Obama's newly funded cost-effectiveness analysis initiative. Basically, how much value does a given product offer to society. VBP is viewed by many as the future of pricing because it combines cost containment with reward for innovation - makes sense, right? Considering in an ideal world, pharmaceutical companies would manufacture drugs with the intent purpose of improving if not prolonging people's lives - adding value to people's lives.Of course, manufacturers argue that VBP is incompatible with getting an actual return on investment. And what if a product fails to show a high enough degree of added value and it's recommended that a drug be priced not necessarily commercially viable?
Seems like a pretty intelligent thing to me. Maybe, this would keep companies from continuing to focus their so-called "innovative research" on developing me-too drugs, and force them to develop truly innovative therapies.
No comments:
Post a Comment